{
"@context": "https://schema.org",
"@type": "Article",
"headline": "Of Drugs and DTC Platforms: American Consumerism, TrumpRx, Telehealth, and the Specter of Congressional Intervention",
"url": "https://www.lexblog.com/2026/02/03/of-drugs-and-dtc-platforms-american-consumerism-trumprx-telehealth-and-the-specter-of-congressional-intervention/",
"identifier": {
"@type": "PropertyValue",
"name": "LexBlog Library record",
"value": "LEX-WK-9CCFB17N",
"url": "https://www.lexblog.com/lib/9CCFB17N/"
},
"datePublished": "2026-02-03T17:11:13-05:00",
"dateModified": "2026-02-04T15:05:05-05:00",
"author": {
"@type": "Person",
"name": "Dominick DiSabatino, Scott Liebman, Julian Klein"
},
"sourceOrganization": {
"@type": "Organization",
"name": "Sheppard, Mullin, Richter & Hampton LLP"
},
"organizationScope": "at-publication",
"about": "Health Care and Life Sciences",
"sourceUrl": "https://www.fdalawblog.com/?p=2348",
"sourceStability": "may-move"
}